Jaimee L Heffner1, Megan M Kelly2,3, Jeanette Waxmonsky4,5, Kristin Mattocks6, Edit Serfozo1, Jonathan B Bricker1,7, Kristin E Mull1, Noreen L Watson1, Michael Ostacher8,9. 1. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA. 2. Edith Nourse Rogers Memorial VA Medical Center, Bedford, MA. 3. Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA. 4. Department of Family Medicine, University of Colorado Anschutz Medical Center, Aurora, CO. 5. Jefferson Center for Mental Health, Wheat Ridge, CO. 6. VA Central Western Massachusetts Healthcare System, Leeds, MA. 7. Department of Psychology, University of Washington, Seattle, WA. 8. VA Palo Alto Health Care System, Palo Alto, CA. 9. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA.
Abstract
INTRODUCTION:Smokers with bipolar disorder (BD) are less successful at quitting than the general population. In this study, we evaluated in a pilot randomized controlled trial a novel, targeted, web-based intervention for smokers with BD based on acceptance and commitment therapy (ACT) and designed for reach and disseminability. AIMS AND METHODS: Daily smokers (n = 51) with bipolarI or II disorder were recruited from four US sites and randomly assigned to one of two web-based smoking cessation interventions-ACT-based WebQuit Plus (n = 25) or Smokefree.gov (n = 26) over a 10-week treatment period. All participants received nicotine patch for 8 weeks. Key outcomes were trial design feasibility, intervention acceptability, and cessation at end of treatment and 1-month follow-up. RESULTS:We screened 119 to enroll 51 participants (target sample size = 60) over 24 months. The most common reason for ineligibility was the inability to attend study appointments. Retention was 73% at end of treatment and 80% at follow-up, with no differences by arm. The mean number of logins was twice as high for WebQuit Plus (10.3 vs. 5.3). The usefulness of program skills was rated higher for WebQuit Plus (75% vs. 29%). Biochemically confirmed, 7-day abstinence at end of treatment was 12% in WebQuit Plus versus 8% in Smokefree.gov (odds ratio = 1.46, 95% confidence interval = 0.21 to 9.97). At follow-up, abstinence rates were 8% in both arms. CONCLUSIONS: Trial design produced favorable retention rates, although alternative recruitment methods will be needed for a larger trial. At end of treatment, acceptability and estimated effect size of WebQuit Plus relative to Smokefree.gov were promising and support continued program refinement and evaluation. IMPLICATIONS: In this first randomized controlled trial of a targeted intervention for smokers with BD, we found that the ACT-based WebQuit Plus intervention, delivered in combination with the nicotine patch, had promising acceptability and cessation outcomes relative to Smokefree.gov. The observed signals for acceptability and cessation suggest that the WebQuit Plus program should be refined based on participant feedback and evaluated in a larger trial. Feasibility findings from this study also provide direction for refining trial procedures to enhance the recruitment of smokers with BD.
RCT Entities:
INTRODUCTION: Smokers with bipolar disorder (BD) are less successful at quitting than the general population. In this study, we evaluated in a pilot randomized controlled trial a novel, targeted, web-based intervention for smokers with BD based on acceptance and commitment therapy (ACT) and designed for reach and disseminability. AIMS AND METHODS: Daily smokers (n = 51) with bipolar I or II disorder were recruited from four US sites and randomly assigned to one of two web-based smoking cessation interventions-ACT-based WebQuit Plus (n = 25) or Smokefree.gov (n = 26) over a 10-week treatment period. All participants received nicotine patch for 8 weeks. Key outcomes were trial design feasibility, intervention acceptability, and cessation at end of treatment and 1-month follow-up. RESULTS: We screened 119 to enroll 51 participants (target sample size = 60) over 24 months. The most common reason for ineligibility was the inability to attend study appointments. Retention was 73% at end of treatment and 80% at follow-up, with no differences by arm. The mean number of logins was twice as high for WebQuit Plus (10.3 vs. 5.3). The usefulness of program skills was rated higher for WebQuit Plus (75% vs. 29%). Biochemically confirmed, 7-day abstinence at end of treatment was 12% in WebQuit Plus versus 8% in Smokefree.gov (odds ratio = 1.46, 95% confidence interval = 0.21 to 9.97). At follow-up, abstinence rates were 8% in both arms. CONCLUSIONS: Trial design produced favorable retention rates, although alternative recruitment methods will be needed for a larger trial. At end of treatment, acceptability and estimated effect size of WebQuit Plus relative to Smokefree.gov were promising and support continued program refinement and evaluation. IMPLICATIONS: In this first randomized controlled trial of a targeted intervention for smokers with BD, we found that the ACT-based WebQuit Plus intervention, delivered in combination with the nicotine patch, had promising acceptability and cessation outcomes relative to Smokefree.gov. The observed signals for acceptability and cessation suggest that the WebQuit Plus program should be refined based on participant feedback and evaluated in a larger trial. Feasibility findings from this study also provide direction for refining trial procedures to enhance the recruitment of smokers with BD.
Authors: Jaimee L Heffner; Robert M Anthenelli; Melissa P DelBello; Lauren Stahl; Stephen M Strakowski Journal: Nicotine Tob Res Date: 2013-06-12 Impact factor: 4.244
Authors: Jill M Williams; Marc L Steinberg; Mia Hanos Zimmermann; Kunal K Gandhi; Gem-Estelle Lucas; Dawn A Gonsalves; Ivy Pearlstein; Philip McCabe; Magdalena Galazyn; Edward Salsberg Journal: J Am Psychiatr Nurses Assoc Date: 2009-02 Impact factor: 2.385
Authors: Mary F Brunette; Joelle C Ferron; Gregory J McHugo; Kristin E Davis; Timothy S Devitt; Sandra M Wilkness; Robert E Drake Journal: Psychiatr Serv Date: 2011-04 Impact factor: 3.084
Authors: K N Roy Chengappa; Kenneth A Perkins; Jaspreet S Brar; Patricia J Schlicht; Scott R Turkin; Michelle L Hetrick; Michele D Levine; Tony P George Journal: J Clin Psychiatry Date: 2014-07 Impact factor: 4.384
Authors: Jaimee L Heffner; Kristin E Mull; Noreen L Watson; Jennifer B McClure; Jonathan B Bricker Journal: Drug Alcohol Depend Date: 2018-10-10 Impact factor: 4.492
Authors: J Lee Westmaas; Lorien Abroms; Jeuneviette Bontemps-Jones; Joseph E Bauer; Jeanine Bade Journal: J Med Internet Res Date: 2011-08-26 Impact factor: 5.428
Authors: Robert M Anthenelli; Neal L Benowitz; Robert West; Lisa St Aubin; Thomas McRae; David Lawrence; John Ascher; Cristina Russ; Alok Krishen; A Eden Evins Journal: Lancet Date: 2016-04-22 Impact factor: 79.321
Authors: Roger S McIntyre; Martin Alda; Ross J Baldessarini; Michael Bauer; Michael Berk; Christoph U Correll; Andrea Fagiolini; Kostas Fountoulakis; Mark A Frye; Heinz Grunze; Lars V Kessing; David J Miklowitz; Gordon Parker; Robert M Post; Alan C Swann; Trisha Suppes; Eduard Vieta; Allan Young; Mario Maj Journal: World Psychiatry Date: 2022-10 Impact factor: 79.683
Authors: Jonathan B Bricker; Brianna M Sullivan; Kristin E Mull; Alula J Torres; Kelly M Carpenter Journal: Nicotine Tob Res Date: 2022-10-17 Impact factor: 5.825
Authors: Erica J Lee; Heather Hower; Richard N Jones; Boris Birmaher; Michael Strober; Benjamin I Goldstein; John Merranko; Martin B Keller; Tina R Goldstein; Lauren M Weinstock; Daniel P Dickstein; Jeffrey I Hunt; Rasim S Diler; Neal D Ryan; Mary Kay Gill; David Axelson; Shirley Yen Journal: J Affect Disord Date: 2020-03-05 Impact factor: 4.839
Authors: Panagiotis Spanakis; Emily Peckham; Ben Young; Paul Heron; Della Bailey; Simon Gilbody Journal: Addiction Date: 2021-11-06 Impact factor: 7.256